Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies
- Junichiro Hirata 1, Takuto Hara 2, Naoe Jimbo 3, Hideto Ueki 1, Yasuyoshi Okamura 1, Yukari Bando 1, Kotaro Suzuki 1, Tomoaki Terakawa 1, Jun Teishima 1, Koji Chiba 1, Hideaki Miyake 1
- Junichiro Hirata 1, Takuto Hara 2, Naoe Jimbo 3
- 1Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
- 2Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan; supermarimo85@gmail.com.
- 3Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.
- 0Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Genomic profiling of Japanese small cell neuroendocrine prostate cancer (SCPC) revealed frequent TP53 and RB1 mutations. While these alterations did not predict platinum chemotherapy response, genomic testing may identify patients eligible for targeted therapies.
Area Of Science
- Oncology
- Genomics
- Prostate Cancer Research
Background
- Small cell neuroendocrine prostate cancer (SCPC) is an aggressive subtype with limited treatment options.
- Understanding the genomic landscape of SCPC is crucial for developing effective therapies.
- Japanese patients with SCPC represent a distinct population for genomic investigation.
Purpose Of The Study
- To investigate the genomic features of SCPC in Japanese patients.
- To assess the relationship between genomic alterations and platinum-based chemotherapy efficacy.
- To evaluate treatment eligibility for targeted therapies based on cancer genomic profiling.
Main Methods
- Retrospective analysis of 21 SCPC patients (2018-2022).
- Pathological review and WHO classification of biopsy specimens.
- FoundationOne® CDx analysis for genomic mutations, including DNA damage repair (DDR) alterations.
- Assessment of progression-free survival (PFS) and overall survival (OS) for chemotherapy efficacy.
Main Results
- DDR mutations found in 38.1% of patients; BRCA mutations in 14.3%.
- TP53 and RB1 mutations were common (71.4% and 57.1%, respectively).
- Genomic mutations did not significantly impact platinum-based chemotherapy efficacy; 28.6% were eligible for approved treatments.
Conclusions
- This study provides the first genomic landscape of SCPC in Japanese patients.
- Genomic mutations, including DDR alterations, were not predictive of platinum chemotherapy response.
- Genomic testing can enhance access to targeted therapies for SCPC, particularly in resource-limited settings.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

